S
Sverre E. Kjeldsen
Researcher at University of Oslo
Publications - 771
Citations - 95426
Sverre E. Kjeldsen is an academic researcher from University of Oslo. The author has contributed to research in topics: Blood pressure & Left ventricular hypertrophy. The author has an hindex of 94, co-authored 735 publications receiving 89059 citations. Previous affiliations of Sverre E. Kjeldsen include University of Michigan & Cornell University.
Papers
More filters
Journal ArticleDOI
The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity
Andreas Moan,Aud Høieggen,Ingebjørg Seljeflot,Terje Risanger,Harald Arnesen,Sverre E. Kjeldsen +5 more
TL;DR: In mildly hypertensive patients, selective angiotensin II receptor antagonism with losartan for 4 weeks lowers blood pressure at rest and during 120 min of glucose clamping, and has neutral effects on insulin sensitivity, glucose metabolism and serum lipids.
Journal ArticleDOI
1999 WHO/ISH Hypertension Guidelines--highlights & ESH update.
Journal ArticleDOI
Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action.
George L. Bakris,Martha N. Hill,Giuseppe Mancia,Krisela Steyn,Henry R. Black,Thomas G. Pickering,S. De Geest,Luis M. Ruilope,Thomas D. Giles,Trefor Morgan,Sverre E. Kjeldsen,Ernesto L. Schiffrin,A Coenen,P Mulrow,A Loh,George A. Mensah +15 more
TL;DR: Tackling the global challenge of hypertension will require partnerships among multiple constituencies, including patients, health-care professionals, industry, media,health-care educators, health planners and governments, as well as local health systems with renewed impetus.
Journal ArticleDOI
Cardiovascular reactivity, coronary risk factors, and sympathetic activity in young men.
TL;DR: Three groups of 19-year-old men, all unaware of their blood pressure status, are studied with intra-arterial blood pressure recordings and multiple measurements of arterial plasma epinephrine and norepinephrine during a mental arithmetic challenge and cold pressor test, with group-99 being hyperreactive compared with the other two groups.
Journal ArticleDOI
Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension
Fadl Elmula M. Fadl Elmula,Yu Jin,Wen-Yi Yang,Lutgarde Thijs,Yi-Chao Lu,Anne Cecilie K Larstorp,Alexandre Persu,Marc Sapoval,Ján Rosa,Petr Widimský,Lotte Jacobs,Jean Renkin,Ondřej Petrák,Gilles Chatellier,Kazuyuki Shimada,Jiří Widimský,Kazuomi Kario,Michel Azizi,Sverre E. Kjeldsen,Jan A. Staessen +19 more
TL;DR: In selected rHT patients maintained on antihypertensive drugs, RDN with the SYMPLICITY systems does not significantly decrease BP but is safe, and future trials with next-generation catheters should aim at identifying responders in patients with evidence of sympathetic nervous overactivity.